Travere Therapeutics (NASDAQ:TVTX) CAO Sells $139,175.96 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sandra Calvin sold 4,333 shares of the company’s stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $32.12, for a total transaction of $139,175.96. Following the transaction, the chief accounting officer owned 49,080 shares of the company’s stock, valued at approximately $1,576,449.60. This represents a 8.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Sandra Calvin also recently made the following trade(s):

• On Wednesday, December 24th, Sandra Calvin sold 7,402 shares of Travere Therapeutics stock. The shares were sold at an average price of $40.00, for a total transaction of $296,080.00.

Travere Therapeutics Price Performance

Shares of NASDAQ TVTX traded down $0.26 during midday trading on Tuesday, reaching $32.84. 1,748,186 shares of the company were exchanged, compared to its average volume of 2,976,006. The stock’s 50-day moving average price is $34.11 and its 200-day moving average price is $27.76. The stock has a market cap of $2.94 billion, a P/E ratio of -30.98, a PEG ratio of 1.01 and a beta of 0.83. The company has a quick ratio of 2.71, a current ratio of 2.75 and a debt-to-equity ratio of 4.23. Travere Therapeutics, Inc. has a one year low of $12.91 and a one year high of $42.13.

Institutional Trading of Travere Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Raymond James Financial Inc. bought a new position in Travere Therapeutics during the 2nd quarter worth approximately $33,000. First Horizon Corp bought a new position in Travere Therapeutics during the third quarter worth $36,000. Torren Management LLC acquired a new position in Travere Therapeutics in the fourth quarter valued at $38,000. Comerica Bank boosted its position in Travere Therapeutics by 77.5% during the fourth quarter. Comerica Bank now owns 1,127 shares of the company’s stock valued at $43,000 after acquiring an additional 492 shares during the last quarter. Finally, Garner Asset Management Corp bought a new stake in Travere Therapeutics during the fourth quarter valued at $69,000.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on TVTX shares. Wall Street Zen raised Travere Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 13th. Citigroup boosted their price target on Travere Therapeutics from $34.00 to $48.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Travere Therapeutics in a report on Wednesday, January 21st. Piper Sandler lifted their target price on shares of Travere Therapeutics from $26.00 to $35.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Finally, HC Wainwright reissued a “buy” rating and set a $47.00 target price on shares of Travere Therapeutics in a report on Friday, November 28th. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Travere Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $38.86.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.